Severe Asthma ToolkitSevere Asthma Toolkit
HomeAboutSpecific PopulationsRegistriesContributorsContact
Twitter
  • What is Severe Asthma?
    • Overview
    • Definition
    • Prevalence & Burden
    • Pathophysiology
    • Symptoms
    • Severe Asthma Attacks / Exacerbations / Flare-ups
    • Asthma Phenotypes
  • Diagnosis & Assessment
    • Overview
    • Diagnosis Overview
    • Assessment Overview
    • Lung Function Assessments
    • Questionnaires
    • Allergy Assessments
    • Phenotyping
    • Bronchoscopy
    • Imaging
    • Occupational Asthma
  • Management
    • Overview
    • Asthma Education
      • About Severe Asthma
      • Asthma Pathophysiology
      • Medications Education
      • Self-Monitoring
      • Triggers
      • Review
    • Written Action Plans
    • Adherence
    • Inhaler Technique
    • Physical Activity & Exercise
    • Interdisciplinary Approach & Multidimensional Assessment
    • Referral
  • Medications
    • Overview
    • Relievers
    • Preventers / Controllers
    • Add-on Therapies
    • Monoclonal Antibodies
    • Bronchial Thermoplasty
  • Co-Morbidities
    • Overview
    • Pulmonary & Upper Airways
      • Allergic & Non-Allergic Rhinitis
      • Chronic Rhinosinusitis
      • Dysfunctional Breathing
      • Vocal Cord Dysfunction
      • Chronic Obstructive Pulmonary Disease
      • Bronchiectasis
      • Obstructive Sleep Apnoea
    • Extra-Pulmonary
      • Obesity
      • Anxiety & Depression
      • Gastro-oesophageal Reflux Disease (GORD)
      • Osteoporosis
      • Cardiovascular Disease & Metabolic Disease
  • Living with Severe Asthma
    • Overview
    • Daily Symptom Burden
    • Mental & Emotional Health
    • Intimacy & Relationships
    • Self-Management Support
    • Medication Use & Costs
    • Experience of Care
    • Experience of Asthma Attacks
    • Prognosis
  • Establishing a Clinic
    • Overview
    • Set-up
    • Staffing & Multidisciplinary Team Approach
    • Facilities
    • Delivery Approach
    • Tailored Referrals
    • Evaluation
    • Opportunities for Training & Research
    • Barriers & Hurdles
  • Paediatrics
    • Overview
    • Management in Paediatrics
    • Assessment in Paediatrics
    • Alternative Diagnosis & Co-Morbidities in Paediatrics
    • Psychosocial Issues in Paediatrics
    • Medications in Paediatrics
    • Asthma in the Adolescent Population
  • Resources
    • Overview
    • Clinic Recommendations
    • Infographics
    • Asthma Assessment Resources
    • Systematic & Multidimensional Assessment Resources
      • Airway Components
      • Comorbidity Components
      • Risk Factor Components
    • Translation & Implementation
    • Case Studies
    • Presentations
    • Videos
    • Relevant Links
    • Key References

Australasian Severe Asthma Registry

Home Registries Australasian Severe Asthma Registry

The Australasian Severe Asthma Registry (ASAR) is a multi-national clinical quality registry of individuals with confirmed severe refractory asthma and non-severe controlled asthma.

ASAR (previously SAWD) was established by the Australasian Severe Asthma Network (ASAN) in 2013.  It is the under the management of the ASAN Steering Committee and governance of the Thoracic Society of Australia and New Zealand (TSANZ).

There are 22 Australasian Severe Asthma Registry (ASAR) centres, located in Australia and New Zealand. Appropriate human research ethics committee/institutional review board and local research governance approvals are in place for the conduct of the registry.

The main purposes of ASAR are:

  1. To describe the heterogeneity of severe asthma and characterise phenotypes.
  2. To identify factors associated with future risk of exacerbations and adverse events.

ASAR also serves as a Databank for future approved research studies.  ASAR is flexible and enables the implementation of new research modules.

Patient enrolment and data collection

Patients with diagnosed severe refractory asthma and non-severe controlled asthma are systematically assessed at registration and followed up prospectively for up to 10-years.   The data is submitted to a secure online database.  The information collected includes non-identifying demographic details, clinical data and patient-reported outcomes.

If you would like to register your interest or for further information, contact:

Laura Mitchell

E/ asar@thoracic.org.au

A/ GPO Box 1491 Sydney, NSW 2001
P/ 02 9222 6200  W/ thoracic.org.au

ASAR is supported by AstraZeneca, GlaxoSmithKline, Novartis and Sanofi.

Previous
Next

Last Updated on May 28, 2020

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

More results...

  • Australasian Severe Asthma Registry
  • Australian Mepolizumab Registry (AMR)
  • Australian Xolair Registry (AXR)

We want to know who accesses the Severe Asthma Toolkit and how it is used. Please complete our survey.

Responses will inform the continued development of the Severe Asthma Toolkit and future translation and implementation activities. Any feedback you provide will be greatly appreciated.

Complete Survey

  • Website Terms of Use
  • Website Survey
© Copyright 2018    CRICOS Provider Number 00109J    The University of Newcastle, Australia